Gain Therapeutics, Inc. (GANX) |
|
3.92 0.04 (1.03%)
|
06-26 18:39 |
|
Open: |
3.9 |
Pre. Close: |
3.88 |
|
High:
|
3.9799 |
Low:
|
3.76 |
|
Volume:
|
76,278 |
Market Cap:
|
47(M) |
|
|
|
|
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.99 - 4 |
4 - 4.02 |
|
Low:
|
3.72 - 3.74 |
3.74 - 3.75 |
|
Close:
|
3.89 - 3.92 |
3.92 - 3.95 |
|
Technical analysis |
as of: 2022-06-24 4:40:11 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 4.64  One year: 5.42 |
| Support: |
Support1: 2.96 Support2: 2.32 |
| Resistance: |
Resistance1: 3.97 Resistance2: 4.64 |
| Pivot: |
3.55 |
| Moving Average: |
MA(5): 3.77 MA(20): 3.42
MA(100): 3.61  MA(250): 5.75 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 87.5 %D(3): 84.8 |
| RSI: |
RSI(14): 63.1 |
| 52-week: |
High: 10.4 Low: 2.32 |
| Average Vol(K): |
3-Month: 171 (K) 10-Days: 78 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GANX ] has closed below upper band by 11.4%. Bollinger Bands are 20.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Sat, 25 Jun 2022
Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson's Disease at XXVII IAPRD World Congress - GuruFocus.com
Wed, 15 Jun 2022
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update - Defense World
Thu, 02 Jun 2022
2022-06-02 | NDAQ:GANX | Press Release | Gain Therapeutics Inc. - Stockhouse
Fri, 27 May 2022
Gain Therapeutics, Inc. (NASDAQ:GANX) Sees Significant Growth in Short Interest - Defense World
Wed, 18 May 2022
Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference - Yahoo Finance
Wed, 11 May 2022
Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
12 (M) |
|
% Held by Insiders
|
8.74e+006 (%) |
|
% Held by Institutions
|
24.3 (%) |
|
Shares Short
|
37 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-1.463e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-8 |
|
Return on Assets (ttm)
|
542.6 |
|
Return on Equity (ttm)
|
-21.4 |
|
Qtrly Rev. Growth
|
171470 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.03 |
|
Qtrly Earnings Growth
|
-1.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
477.19 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
78050 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
